6.51 +0.05 (0.76%)
PLX
| Trade PLX now with |
|
Stock Details
Last Trade:6.51 Change:+0.05 (0.76%) Prev Close:6.46 Open: 6.56 Days Range:6.40 – 6.56 52 Week Range: 4.06 - 10.40 Volume:286597 P/E: 72.33EPS:0.09
View AllRecent Alerts 02/09/12
Recent Alert on 01/26/12 at 11:20am
Canaccord Genuity on Life Sciences/Biotechnology: Forex Exposure - Impact ITMN, PLX, AEGR & ONXX
Canaccord Genuity on Life Sciences/Biotechnology: Forex Exposure - Impact ITMN, PLX, AEGR & ONXX
Canaccord Genuity on Life Sciences/Biotechnology: Forex Exposure - Impact to covered stocks Analyst, Ritu Baral, said, "Recent weakness in the Euro has heightened investor concern that companies relying significantly on European revenues may show... Read More
Recent Alert on 12/06/11 at 1:12pm
Unusual 11 Mid-Day Movers 12/06: (AMR) (PPHM) (FRO) Higher; (CMED) (XING) (PLX) Lower
Unusual 11 Mid-Day Movers 12/06: (AMR) (PPHM) (FRO) Higher; (CMED) (XING) (PLX) Lower
Recent Alert on 12/06/11 at 11:09am
Protalix (PLX) Shares Hit as FDA Extends Taliglucerase Alfa PDUFA by Three Months
Protalix (PLX) Shares Hit as FDA Extends Taliglucerase Alfa PDUFA by Three Months
Recent Alert on 12/06/11 at 11:09am
Protalix (PLX) Shares Hit as FDA Extends Taliglucerase Alfa PDUFA by Three Months
Protalix (PLX) Shares Hit as FDA Extends Taliglucerase Alfa PDUFA by Three Months
Recent Alert on 12/06/11 at 11:05am
Morning Movers 12/06: (PPHM) (AMR) (FRO) (OWW) Higher; (CMED) (PLX) (XING) (MTL) Lower
Morning Movers 12/06: (PPHM) (AMR) (FRO) (OWW) Higher; (CMED) (PLX) (XING) (MTL) Lower
View AllRecent Press Releases
Press Release on 02/09/12 at 2:00am
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium
Protalix Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 12/07/11 at 9:17am
Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point
Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point